Core Viewpoint - Insulet's stock surged nearly 10% following a strong Q3 performance, with sales of $544 million and adjusted earnings of $0.90 per share, exceeding consensus estimates [1][2]. Financial Performance - Insulet reported a revenue of $544 million, reflecting a 26% year-over-year growth, with U.S. and International Omnipod sales growing by 23% and 36%, respectively [2]. - The adjusted EBITDA margin increased by 410 basis points year-over-year to 23.2% in Q3, contributing to an adjusted earnings per share of $0.90, up from $0.71 in the prior-year quarter [2]. Future Outlook - The company anticipates sales growth of 20% to 21% in 2024, an increase from the previous outlook of 16% to 19% [2]. Stock Performance - Insulet's stock (PODD) has gained 23%, performing in line with the S&P 500 index, which is up 25% [3]. - The stock's performance has been volatile over the past three years, with returns of 4% in 2021, 11% in 2022, and -26% in 2023 [3]. Valuation Perspective - The stock is currently priced around $270, trading at 11 times trailing revenues, compared to an average price-to-sales ratio of 14 times over the last three years [4]. - The decline in valuation appears justified due to potential long-term impacts from new GLP-1 drugs on Insulet's sales, which may reduce demand for insulin pumps [4].

Insulet Corporation (NASDAQ:PODD) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President of Investor Relations Jim Hollingshead - President and Chief Executive Officer Ana Maria Chadwick - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Lawre ...

| --- | --- | --- | |--------------------|-------------------|-------| | | | | | | Mattie | | | | Podder since 2010 | | | Q3'24 Earnings | | | | November 7, 2024 | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimate ...

Core Insights - Insulet reported $543.9 million in revenue for Q3 2024, a year-over-year increase of 25.7% and a surprise of +4.90% over the Zacks Consensus Estimate of $518.5 million [1] - The EPS for the same period was $0.90, compared to $0.71 a year ago, resulting in a surprise of +16.88% over the consensus estimate of $0.77 [1] Revenue Breakdown - International Omnipod revenue reached $138 million, exceeding the six-analyst average estimate of $123.11 million, with a year-over-year change of +36.1% [3] - U.S. Omnipod revenue was $395.60 million, surpassing the six-analyst average estimate of $391.62 million, reflecting a year-over-year change of +23.4% [3] - Total Omnipod revenue amounted to $533.60 million, exceeding the six-analyst average estimate of $514.73 million, with a year-over-year change of +26.5% [3] - Drug Delivery revenue was reported at $10.30 million, compared to the $3.28 million average estimate, showing a year-over-year change of -3.7% [3] Stock Performance - Insulet's shares have returned +3.2% over the past month, matching the Zacks S&P 500 composite's +3.2% change [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]

Company Performance - Insulet reported quarterly earnings of $0.90 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, and up from $0.71 per share a year ago, representing an earnings surprise of 16.88% [1] - The company posted revenues of $543.9 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.90%, compared to year-ago revenues of $432.7 million [2] - Insulet has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] Stock Outlook - Insulet shares have increased approximately 10.3% since the beginning of the year, while the S&P 500 has gained 24.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.02 on revenues of $564.54 million, and for the current fiscal year, it is $3.04 on revenues of $2.01 billion [7] Industry Context - The Medical - Products industry, to which Insulet belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]

Table of Contents _____________________________________________________ ________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...

Exhibit 99.1 Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency ) 1 Raising Full Year Revenue and Margin Guidance ACTON, Mass. - November 7, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended September 30, 2024. ® "We continue to achieve significant milestones and robust revenue growth," said Jim ...

Insulet’s (PODD) robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD carries a Zacks Rank #2 (Buy) currently.Factors Driving PODD StockInsulet is making significant strides in its key strategic imperatives to help patients manage diabetes efficiently.  The company’s first strategy revolves around increasing access and awareness of Omnipod products. In the second quarter of 2024, ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size ...

Insulet Corporation (PODD) is driving share gains with its prime Omnipod 5 AID (automated insulin delivery) system, which is highly promising for growth in the upcoming quarters. The company continues to expand the platform to new countries with sensor integrations. A strong solvency position also bodes well for the stock. However, the mounting costs of Omnipod 5 production, coupled with its excessive reliance on this offering, raise concerns for the company.In the past year, this Zacks Rank #2 (Buy) stock ...